►
From YouTube: Open Source Antibiotics Science Update Mar 12 2021
Description
Weekly open project meeting for Open Source Antibiotics Series 2.
Full Project: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles
Relevant GitHub Issue: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles/issues/59
On the call: Professor Matthew Todd, Dr Dana Klug, Giada Sabatino, Dr Lori Ferrins (Northeastern University), Anthony Sama (citizen scientist).
A
Times
and
where
we
are
all
right,
so
let
me
share
screen,
because
I
I
think
we've
got
just
a
few
things
to
talk
about
today's
12th
of
march.
That's
antibiotics,
series
2.
here
we
are
so
I
was
the
the
first
thing
I
was
going
to
just
mention
is
the
some
of
the
sar
for
this
series.
A
So
you
know
we
have
been
doing
a
lot
of
stuff
with
motifs
a
little
bit
like
this,
where
you
know
we
found
that
we
need
this
chelating
two
pyradil
thing
and-
and
and
you
know
you
can-
you
can
vary
this
ring
a
little
bit
and
we've
been
playing
with
aromatic
rings,
joined
directly
to
this
five-membered
ring
and
we
we
were
having
issues
with.
A
You
know,
toxicity
that
was
tracking
with
potency
and
we
were
having
a
ceiling
on
the
potency
and
then
we've
evaluated
some
molecules
like
this
more
recently
from
lori's
compounds
and
suddenly
found
that
we
we
have
some
potency
and
potentially
a
selectivity
index
a
decent
selectivity
index,
but
we
need
to
confirm
that
so
the
most
important
thing
that's
going
on
is
that
these
compounds
have
now
gone
to
to
alex
for
potency.
A
For
toxicity
evaluation,
which
is
great
at
the
same
time,
the
the
molecules
that
we
evaluated
for
talks
last
time
are
going,
I
think,
to
laurie
right
for
evaluation
in
dndi's
toxicity
assay,
that's
right!
Dana!
Isn't
it
that
we
are.
B
Yes
right
so
I
haven't
confirmed
that
with
ben.
I
don't
think,
but
that
should
be
fine,
provided
we
have
enough
material.
I
think.
A
Yes,
I
think
so.
I
think
that
lori
was
offering
some
screening
in
the
dndi
kind
of
pathway
for
toxicity
and
other
things
it
turns
out,
but
one
of
the
reasons
for
doing
that
is
to
sort
of
double
check,
their
toxicity
assay
versus
ours
right
that
was
an
email.
She
we
volunteered
at
last
time
that
she
sent
a
follow-up
email
and
we
said
that
yeah
we'd
probably
send
them
directly
to
her
and
she
can
sort
of
install
them
in
her
essay
and
get
them
screened,
which
would
be
very
good.
A
A
A
Are
these
and
I
was
looking
at
these
last
night?
I
was
thinking
if
these
came
from
that
dndi
project
then
hang
on.
How
do
these
relate
to
the
previous
compounds
that
dndi
sent
us
because
my
my
memory
was
was
weak,
but
I
seem
to
remember
that
those
comments
came
through
and
they
weren't
very
good.
So
I
I
searched
through
them
and
found
them
back
in
issue
35,
and
it
was
these
guys
right
that
were
sent
from
there
and
yeah
they've
got
they've.
So
there
were
some
com.
A
There
were
some
conclusions
from
this,
but
they
were
they're
a
little
bit
tricky.
We
sort
of
found
that
some
of
these
five
member
rings
weren't
working
stuff,
but
the
most
interesting
conclusions
from
these
were
these
guys.
I
think
over
here,
where
we've
got
the
collating
two
period
motif
and
we've
got
a
bunch
of
other
things
going
on
whatever,
but
we've
got
the
nitrogen
and
we've
got
the
pendant
ring
here,
which
is
the
kind
of
thing
that
we
have
in
you
know
the
compounds
that
we
were
just
looking
at
oops.
A
Sorry,
I've
just
lost
the
place
in
them.
You
know
these
guys
here
right.
So
it's
the
same
basic
motif:
we've
got.
You've
got
the
the
the
same
ring
system,
the
two
paradigm
motif
nitrogen
aromatic
ring.
So
I
was
thinking.
Okay,
hang
on
a
minute.
What's
going
on?
What
have
we
learned
here
and
the
thing
we
learned
of
course?
Well,
the
thing
that
this
is
screaming
out
is
that
when
this
is
nh,
it's
no
good
and
when
it's
unalkalated
we
get
potency.
B
A
Right-
and
I
was
thinking
okay,
I
I
should
have
realized
that,
and
that
should
be
foremost
in
my
mind
when
I'm,
when
I'm
thinking
about
understanding
the
sar
and
so
one
of
the
issues
which
I'm
going
to
put
on
you
daniel
and
an
ad,
because
I
think
that
ed
is
back
full
time
on
with
us
on
like
from
next
week
is,
is
to,
I
guess,
update
the
essay
on
the
wiki.
C
Like
same
conclusion,
that
you
did
with
the
alkylation
and
there
was
that
paper
from
dndi
into
cada,
where
the
two
lead
compounds
the
there
were
the
two
lead
compounds
in
the
paper
that
were
derived
from
cyclo
cyclopentyl
and
tert-butyl
isocyanide
respectively.
C
I
was
thinking
those
are
commercially
available,
so
you
can
get.
You
know
dana
if
you're,
if
you're
able
to
you,
can
get
maybe
tb,
unc
and
cyclopentyl
and
do
the
one
pot
and
then
alkylate
using
ethyl
bromide.
A
I
guess
I
guess
the
the
thing
I'm
trying
to
emphasize
here
is
that
we
need
to
two.
I
mean
two
things.
One
is
just
to
make
sure
that
we
we
heavily
have
ceremonies,
and
it's
like
the
least
glamorous
thing
of
all
to
do.
You
know
this
nice
tedious
thing
to
aggregate
the
debt
if
we
have
to,
because
I
think
that's
something
something
very
specific
here.
We
have
to
make
sure
the
talks
window
is
there,
so
that's
not
too
excited,
but
certainly
that's
the
most
important
thing
and
the.
D
A
Thing,
though,
is
that
we
need
to
start
writing
up
the.
This
is
the
paper
anyway,
because
we've
got
to
get
something
out,
and
so
it's
not
a
bad
idea
to
start
thinking
about.
Well,
what
are
the
sar
themes
for
a
writer-
and
this
is
a
clear
case
of
something
we've
learned
from
from
screening,
a
bunch
of
companies
which
were
contributed.
A
E
Good
morning
afternoon,
sorry,
I'm
late,
so
I
just
on
on
this
particular
point,
so
I
actually
sent
dana
a
file
this
week
with
a
bunch
of
structures,
so
I
basically
went
through
and
had
a
look
at
anything
and
everything
that
we
have
on
hand
here
at
northeastern
and
look.
We
don't
have
very
many
and
alcohols,
because
that's
something
sort
of
relatively
new
that
we've
been
trying.
E
Having
said
that,
we
have
a
bunch
of
material
that
we
could
potentially
alkylate,
and
so
we're
actually
looking
at
the
moment
to
see
one
which
of
those
actually
makes
sense
in
terms
of
our
sar
like
for
chagas
and
leash.
Do
we
want
to
be
and
alkylating
those
and
then
the
other
part
is
as
well?
I
could
potentially
get
an
undergraduate.
E
I
think
I've
got
one
coming
in
over
summer
who
could
potentially
work
on
actually
alkalating
everything
else.
You
know
kind
of
like
a
second-tier
priority
list.
As
far
as.
E
Yep
but
yeah,
so
I
guess
what
I
was
trying
to
say
is
we're
hoping
to
be
able
to
generate
some
more
and
so
I'm
just
waiting
yeah
to
basically
start
doing
some
of
that
and
I'm
hoping
to
be
able
to
post
that
on
github
shortly,
just
with
like
a
full
list
of
everything
that
we
are
proposing
to
do.
A
Okay,
great,
that's,
that's
awesome,
I
mean
yeah,
it
does
depend
on
on
the
talks.
Obviously,
but
I
just
I
guess
you
know,
the
main
learning
as
they
say
from
from
here
is,
is
that
that
is
a
key
motif.
So
there
are
other
things
we
haven't
tinkered
with,
as
we
were
talking
about
last
time.
The
substitution
of
the
pyradine
and-
and
some
of
these
rings
in
theory
could
be
productive
for
us,
because
they've
all
been
tested
here
with
the
free
nh.
C
A
A
Yeah
these
are,
I
mean
the
yeah
yeah,
okay,
all
right,
so
I
just
wanted
to
emphasize
that
I
mean
in
the
sense
that
you
know
again
with
with
paper
we're
doing
this
with
the
open
source
malaria
paper.
You
know
we're
going
to
be
selecting
out
some
key
things
for
the
for
the
paper
here
and-
and
you
know
these
will
all
appear
in
the
supporting
information.
A
Obviously,
but
but
in
terms
of
our
understanding,
we're
zooming
in
pretty
strongly
on
the
an
alcohol
at
the
moment,
all
right-
so
that's,
I
guess
that's
just
to
you
know
to
flag
up
that
support,
but
that's
that's
great
to
hear
why
thank
you
and
thanks
to
anthony
for
the
for
the
thing
in
the
in
the
chat
winner.
That's
great
all
right!
So
so
these
compounds
are
now
with
alex.
A
I
guess
we'll
we'll
have
to
have
an
update
at
some
point
next
week
about
you
know
what
the
time
scale
is
there,
because
that's
kind
of
a
crucial
experiment.
I
don't
think
alex
is
committed
to
a
time
frame
here
because,
of
course,
he's
busy
with
a
lot
of
other
things,
but
do
you
have
a
sense
of
it?
I
mean
last
time
it
was.
It
was
a
couple
of
weeks
right
at
least.
B
Yeah,
I
think
this
time
it
should
be
quicker
because
they've
got
the
cell
line
up
and
running
and
they
don't
have
to
validate
the
assay
and
things
like
that,
so
I'm
hoping
it'll
be
quicker,
but
I
can
check-
and
I
just
dropped
the
compounds
off
yesterday,
so
I'll
check
in
with
her
maybe
end
up
next
week
to
see
how
she's
going-
and
I
told
I
did
tell
her-
that
we
wanted
to
start
with,
I
think
983,
which
is
the
one
that
showed
that
it
was
way
less
toxic
in
the
mrc
5
assay.
A
Good
separately
to
that
set
flavio
can't
join
us
posted
some
stuff
last
time
of
of
combat.
So
there's
some
compounds
that
he's
he's
looked
through
in
this
excel
sheet.
That
he's
posted
and
some
other
compounds
that
he
can.
He
can
sort
of
derivatize
fairly
quickly,
based
on
the
project
that
he
was
doing,
and
so
the
thing
that
strikes
me
about
some
of
these
and
it's
great,
he
did
this.
I
think
I've
hang
on.
I'm
gonna
have
to
switch
windows,
wait
a
minute.
A
Zoom
doesn't
perceive
that
I'm
no
longer
looking
in
that
space,
so
the
the
things
he
posted
here
loads
of
data
in
here
really
good.
But
essentially,
I
think
all
of
the
compounds
do
not
possess
the
methyl
chelation
possibility
so
they're,
all
basically
pendant
fennel
rings,
and
so
I'm
not
sure
any
of
these
are
worth
looking
at.
A
To
be
frank,
just
because
we
kind
of
know
that,
when
we're
unlikely
to
get
anything
and
of
the
says
the
first
thing
of
the
other
things,
let
me
just
go
back
to
the
original
screen,
which
I
think
is
that
one
of
the
other
things
here
again.
The
rings
that
he's
thinking
about
functionalizing
don't
offer
much.
Maybe
apart
from
this
guy
down
here,
offer
much
of
a
massive
collision
possibility.
So
I'm
just
not
sure
it's
worth
our
asking
him
for
for
samples
or
further
chemistry
there.
A
Until
I
mean
it
seems
like
a
plan
b,
is
to
sort
of
start
branching
out
to
other
things
that
even
if
samples
are
available,
I
guess
we
shouldn't
you
know
we
shouldn't
get
too
distracted.
It's
my
sense.
C
We
haven't
tried,
though
the
final
piece
I
feel
like
to
put
the
two
pi
pure
dial
to
bed,
which
is
an
alkylated
compound
with
fennel
or
four
pirate
aisle
in
place
of
the
ring
that
we
normally
would
need
to
periodical.
A
Now
the
counter
thing
is:
is
I
think
that
flavio
is
happy
to
take
our
sheet
and
screen
through
the
master
list
and
see
if
there's
anything,
that's
of
interest
to
him,
but
that
I
guess
that's
I
mean
we
can
provide
those
compounds,
but
that's
that's
on
him
to
request
them.
If
you
like
them,.
B
A
Oh
yeah,
I
had
a
question
about
that.
I
was
looking
at
the
the
sheet
and,
of
course,
the
sheet
the
masterlist
was
designed
for
initially
for
the
fragments
that
we
had.
I
I
may
have
been
going
crazy,
but
I
didn't
see
a
column
for
potency.
B
So
the
the
first
tab
is
just
a
list
of
all
of
them
and
I
think
it
has
like
the
inchi
key
and
things
like
that
and
then
the
there's
other
tabs
down
at
the
bottom
and
that's
where
the
data
is
so.
The
series
two
tabs
should
have
all
the
talk
data,
any
admin,
data
that
we've
gotten
from
laurier
elsewhere
and
and
everything
and
the
potency
as
well.
A
Okay,
all
right
great
okay,
so
those
are
the
main
things
we're
getting
the
the
talks
done
and
we're
formulating
compounds
to
to
send
to
you,
lorry
and
and
we're
we're-
I
guess,
updating
the
sar
so
that
we
are
able
to
make
sure
that
we're
focusing
in
the
right
direction.
A
That's
all
good!
The
mechanism
of
action
is
stalled
until
we
get
a
better
sense
of
that
selectivity
index
and
the
in
vitro
pk
danny
you're
busy
with
lots
of
other
things,
but
eventually,
eventually
the
hypha
sample
will
be
looked
at.
A
I
mean
without
that
lack
of
weight
for
the
moment,
and
so
all
of
the
things
I
want
to
talk
about
that
was
everything
on
the
mechanism
of
action.
Stuff,
giardia,
you've
been,
you
know,
looking
at
potential
targets,
have
you
got
anything
you
want
to
say
I'm
getting
again
and
put
you
on
the
spot.
You
don't
think
you
want
to
say
about.
You
know
modeling
you're,
looking
at
with
with
molecules
that
look
like
they're
collating,
metals
ions
in
in
the
middle
of
metalloenzymes.
F
F
And
I
asked
to
some
experts
in
regarding
this,
and
maybe
I
can
try
to
change
some
comments
in
order
to
make
the
program
to
improve
the
program
and
set
this
in
order
to
make
it
better
in
order
to
kill
it.
Regarding
the
evacuation
and
yeah,
I
yeah.
F
Yeah
also
because
I'm
not
really
sure
that
the
program
is
good
enough,
and
maybe
I
should
change
some
settings
in
order
to
have
a
better
interactions
with
metals.
So
I
I
I'm,
I'm
checking
it
and
yeah
I'll.
Let
you
know,
of
course,
great.
B
Got
a
couple
of
them
to
come
clean,
so
yeah.
My
plan
for
next
week
is
to
keep
working
on
the
ones
that
I
had
made
that
just
were
not
pure
and
then
do
some
of
the
one
pot
chemistry
with
those
heterocycles
that
we
had
discussed
previously,
like
back
in
december.
A
January,
all
right
great
thanks.
Everyone
for
joining
lori,
we'll
we'll
be
in
touch
about
you-
know
molecules
to
ship
to
you
following
your
very
kind
of
and
we'll
we'll
take
that
off
this
meeting.
A
All
right
thanks,
very
much!
Everybody
really
good
and
stay
in
touch,
see
you
next
time
have
a
good
rest
of
the
week.